Entasis Therapeutics Holdings Inc (ETTX)

NASDAQ
2.500
-0.110(-4.21%)
  • Volume:
    69,662
  • Bid/Ask:
    2.500/2.700
  • Day's Range:
    2.500 - 2.620

ETTX Overview

Prev. Close
2.61
Day's Range
2.5-2.62
Revenue
-
Open
2.61
52 wk Range
1.58-3.73
EPS
-1.74
Volume
69,662
Market Cap
108.95M
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
-
P/E Ratio
-
Beta
-
1-Year Change
-16.94%
Shares Outstanding
43,579,229
Next Earnings Date
Nov 18, 2021
What is your sentiment on Entasis Therapeutics Holdings Inc?
or
Market is currently closed. Voting is open during market hours.

Entasis Therapeutics Holdings Inc News

Entasis Therapeutics Holdings Inc Analysis

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong SellStrong SellStrong SellSellSell
Technical IndicatorsStrong SellStrong SellStrong SellNeutralStrong Sell
SummaryStrong SellStrong SellStrong SellNeutralStrong Sell

Entasis Therapeutics Holdings Inc Company Profile

Entasis Therapeutics Holdings Inc Company Profile

Employees
47

Entasis Therapeutics Holdings Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel antibacterial products to treat serious infections caused by multi-drug resistant gram-negative bacteria in the United States. Its lead product candidate is sulbactam-durlobactam (SUL-DUR), a novel IV antibiotic that is in Phase III clinical trial for the treatment of Acinetobacter baumannii. The company also develops Zoliflodacin, a novel orally administered molecule, which is in Phase III clinical trial for the treatment of uncomplicated gonorrhea; ETX0282CPDP, an oral drug that is in Phase I clinical trial for the treatment of urinary tract infections; and ETX0462, a drug candidate from NBP platform that is in pre-clinical stage for the treatment of multidrug-resistant gram-negative infections. The company has a license and collaboration agreement with Zai Lab (Shanghai) Co., Ltd. for the development of durlobactam and SUL-DUR; and collaboration agreement with Global Antibiotic Research and Development Partnership for the development and commercialization of a product candidate containing zoliflodacin. Entasis Therapeutics Holdings Inc. was founded in 2015 and is headquartered in Waltham, Massachusetts.

Read More
  • Trash
    1
    • why Mr. Byrde , trash ? can you explain to me ? please ? i am asking you very gently and friendly like old friends. please if you can help me i will appreciate so much .
      4
    • Typical pump and dump....Might be a while before this one exceeds
      0
    • Marty Byrde go climb to some tree to catch some banana
      0
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.